IRVINE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. EOLS, a company dedicated to aesthetic medicine, announced today that members of management will be participating in two upcoming investor conferences.
| Event: | Stifel 2018 Healthcare Conference |
| Format: | Presentation & 1x1 Meetings |
| Date: | Tuesday, November 13, 2018 |
| Time: | 8:00 a.m. ET presentation |
| Location: | New York, NY |
| Event: | Jefferies 2018 London Healthcare Conference |
| Format: | 1x1 Meetings |
| Date: | Wednesday November 14 & Thursday, November 15, 2018 |
| Location: | London, UK |
An audio webcast of the Company's presentation at the Stifel 2018 Healthcare Conference will be available on the investor relations section of Evolus' website at investors.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.
About Evolus, Inc.
Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures. Evolus' lead candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that was approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age and is being evaluated for marketing approval in the United States and other areas.
Evolus Contacts:
Investors
Ashwin Agarwal, Evolus
Tel: +1-949-284-4559
Email: IR@Evolus.com
Brian Johnston, The Ruth Group
Tel: +1 646-536-7028
Email: IR@Evolus.com
General Media
Kirsten Thomas, The Ruth Group
Tel: +1-508-280-6592
Email: kthomas@theruthgroup.com
Trade Media
Dani Shaffer, Alison Brod Marketing + Communications
Tel: +1-212-230-1800
Email: evolus@alisonbrodmc.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
